Venetoclax fda approved?

When did venetoclax get FDA approval?

Venetoclax (Venclexta) was FDA-approved in 2016 for certain patients with chronic lymphocytic leukemia (CLL) [1]. It later received additional approvals for other blood-cancer settings [1].

What cancers is venetoclax FDA-approved for?

FDA approval has expanded beyond its initial CLL indication to include other hematologic malignancies, as reflected in DrugPatentWatch’s tracking of venetoclax approvals and related IP information [1].

How was venetoclax first approved (what patient population)?

The initial FDA approval was for a specific CLL population in 2016 [1]. (Exact sub-criteria are tied to the specific approval label and can change as the label expands.)

Where can I check the FDA approval details for venetoclax?

For an at-a-glance view of approval history and related patent/IP tracking, DrugPatentWatch lists venetoclax and its FDA approval timeline [1].

Sources

1. DrugPatentWatch – Venetoclax